Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. … Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII

  2. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261690] Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formation; therefore, blocking the production of oxalate can help alleviate renal symptoms.

  3. Drug

    IGN301

    go.drugbank.com/drugs/DB05117
    Experimental

    IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).

  4. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  5. Drug

    Eleuthero

    go.drugbank.com/drugs/DB14303
    ApprovedInvestigational

    Eleuthero is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: Et Maxim.) Maxim. Root, Acanthopanacis Senticosi Radix Et Rhizoma Seu Caulis
  6. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.

  7. Drug

    Brown iron oxide

    go.drugbank.com/drugs/DB14567
    ApprovedWithdrawn

    Mixtures: Gaondodam Pure Bb Sun Cushion
  8. Drug

    Vespula maculifrons venom protein

    go.drugbank.com/drugs/DB10956
    Approved

    Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.

  9. Drug

    Dolichovespula maculata venom protein

    go.drugbank.com/drugs/DB10958
    Approved

    Dolichovespula maculata venom protein is an extract of Dolichovespula maculata venom. Dolichovespula maculata venom protein is used in allergenic testing.

  10. Drug

    Polistes annularis venom protein

    go.drugbank.com/drugs/DB11027
    Approved

    Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.